about
Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence qualityProblems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris.Comparative study of enema retention and preference in ulcerative colitisNicotine: does it have a role in the treatment of skin disease?Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study).Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity.Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy.Interpreting outcome measures and defining treatment success.The evolution of clinical guidelines for dermatologists: GRADE, AGREE and occasionally consensus by experts.Potential danger of hair dyes marketed as free from para-phenylenediamine.Towards global consensus on core outcomes for Hidradenitis Suppurativa research: An update from the HISTORIC consensus meetings I and II.Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine.Plasma fibrinogen in ulcerative colitis: the effect of disease activity and nicotine therapy in a randomised controlled trial.Occupational allergic contact dermatitis to polyfunctional aziridine crosslinker in a 'tufter'.A randomized trial of nicotine enemas for active ulcerative colitis.Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance.Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool.Systematic reviews: let's keep them trustworthy.NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?How to write a Critically Appraised Topic: evidence to underpin routine clinical practice.Case reports in dermatology: loved by clinicians, loathed by editors, and occasionally important.Optimizing case reports and case series: guidance on how to improve quality.Clinician surveys - time to make better use of this valuable resource for dermatologists.BJD support for dermatology journal clubs: nurturing Sir William Osler's legacy.Segmental cherry angiomas associated with extragenital lichen sclerosus: a report of two cases.Difficulty giving feedback on underperformance undermines the educational value of multi-source feedback.A Core Domain Set For Hidradenitis Suppurativa Trial Outcomes: An International Delphi Process.Absence of pathogenic γ-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa)The natural history of eczema from birth to adult life: a cohort studyCombination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?The aetiology of acne inversa: an evolving storyAdalimumab vs Methotrexate for the Treatment of Chronic Plaque PsoriasisAll patients with sebaceous gland neoplasms should be screened for Muir-Torre syndromeThe pharmacology of itchBritish Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018The pharmacology of itch
P50
Q28074160-910A98D6-2848-4672-B186-09C20BCA842AQ34025749-82C21BAB-C9D7-4D0E-B976-71D944DE8FBEQ35522628-656B1050-6362-4172-BEF0-C3302BC4A4B1Q37471121-77B3C491-9644-4440-B4BC-2ED513592295Q37505028-4A593BDC-290F-4855-B310-5952922B6008Q37681319-FE2FAE3D-EB83-4BB4-9DE9-237EC67DF31CQ38732070-05447300-B628-4E81-A398-862614D5AE31Q40124067-799F6037-9FCF-4219-8355-FAAAE4E64110Q40163694-F5B30274-EB0C-4B9E-90FB-A9243162AE84Q44065983-1AABE44D-8C7C-471D-8047-DB0A67D51617Q44186924-D174D4CA-46E9-49EF-BE55-C861FCA8C29DQ44689442-2272B80D-ECDE-42B9-9A5E-F57F1FC47C13Q44974556-77BF403D-29FE-420A-9087-DE294DCBBE55Q45071242-9BED4894-8B54-4404-88D5-07F165A4CB10Q45103011-DD758498-9521-4D14-B9DA-5174F14F61FEQ46708812-914936AF-B1EF-47FA-A015-AA6C79C2DF7CQ46750737-2D1F5A0B-854A-48F4-BFE9-12737D913EA5Q46791653-5976F9BA-0E7E-45E4-A735-048184D1A50CQ46819064-F688BBBB-6B7F-49AE-B545-55BD60FAC2C6Q47623064-D75EAB3D-0277-4C1F-B821-9C82C66667DDQ48126276-A860F828-276D-499E-BE33-D6DD6BA0DBB6Q48156138-87E39FFD-ADAB-43D2-AA9F-0D2AE3D607BDQ48187188-1FF1FD3A-985A-4276-A2EA-4F267CAC95A6Q48262032-EE36B909-9577-4916-8AED-713F0E5997C0Q48352789-9CD7A09B-D026-4667-813E-D3AED75AD933Q49928861-80A74C68-8F24-4BAE-8460-2D30B7321A29Q49997616-015ABF5B-9E52-494F-A0A6-0843D14CDD51Q50020723-55E3E256-6E19-4CD1-AA42-5311CE3F2F89Q50492862-77D82AC6-94F3-482F-BB29-169A94360258Q50736612-B469B9FC-4DDF-447A-A17B-75605818CB8DQ52588824-2A5E6B2B-342A-4DCF-A155-2B978093CFA6Q59300713-0BF7E314-64D9-49C8-A3A4-0E62035C1794Q59300729-62496019-DE00-4D24-8FD9-4C77C5D8D7DDQ59300741-7F8CC652-B108-42B5-876A-7EEC250A9AAAQ59300760-A8064283-3498-45F1-A917-1443094BC973Q59300780-5CE0EA32-20DB-4DD7-BC8E-CB547E036969Q59300790-EA5B73D4-F489-41F5-9697-60AD229125DEQ90443297-8AB9B534-2801-408F-9960-6E1F5BAA73C2Q90535643-26777703-ADBD-459A-97E3-5A0277F59D8CQ90708484-2050BC35-7304-447F-93B1-7F91DFB02879
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-5257-1142
@en
name
John R. Ingram
@ast
John R. Ingram
@en
John R. Ingram
@es
John R. Ingram
@nl
John R. Ingram
@sl
type
label
John R. Ingram
@ast
John R. Ingram
@en
John R. Ingram
@es
John R. Ingram
@nl
John R. Ingram
@sl
prefLabel
John R. Ingram
@ast
John R. Ingram
@en
John R. Ingram
@es
John R. Ingram
@nl
John R. Ingram
@sl
P106
P1153
9038568600
P21
P31
P3835
john-ingram3
P496
0000-0002-5257-1142